CA2471147C - Nitric oxide donors for treatment of disease and injury - Google Patents

Nitric oxide donors for treatment of disease and injury Download PDF

Info

Publication number
CA2471147C
CA2471147C CA2471147A CA2471147A CA2471147C CA 2471147 C CA2471147 C CA 2471147C CA 2471147 A CA2471147 A CA 2471147A CA 2471147 A CA2471147 A CA 2471147A CA 2471147 C CA2471147 C CA 2471147C
Authority
CA
Canada
Prior art keywords
cells
rats
sildenafil
brain
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2471147A
Other languages
English (en)
French (fr)
Other versions
CA2471147A1 (en
Inventor
Michael Chopp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry Ford Health System
Original Assignee
Henry Ford Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry Ford Health System filed Critical Henry Ford Health System
Publication of CA2471147A1 publication Critical patent/CA2471147A1/en
Application granted granted Critical
Publication of CA2471147C publication Critical patent/CA2471147C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2471147A 2002-01-04 2003-01-06 Nitric oxide donors for treatment of disease and injury Expired - Fee Related CA2471147C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34547802P 2002-01-04 2002-01-04
US60/345,478 2002-01-04
PCT/US2003/000323 WO2003056899A2 (en) 2002-01-04 2003-01-06 Nitric oxide donors for treatment of disease and injury

Publications (2)

Publication Number Publication Date
CA2471147A1 CA2471147A1 (en) 2003-07-17
CA2471147C true CA2471147C (en) 2010-08-10

Family

ID=23355218

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2471147A Expired - Fee Related CA2471147C (en) 2002-01-04 2003-01-06 Nitric oxide donors for treatment of disease and injury

Country Status (9)

Country Link
US (2) US20050143388A1 (enExample)
EP (1) EP1469852A4 (enExample)
JP (2) JP4545440B2 (enExample)
CN (1) CN1638775A (enExample)
AU (1) AU2003210447B2 (enExample)
CA (1) CA2471147C (enExample)
IL (1) IL162850A0 (enExample)
WO (1) WO2003056899A2 (enExample)
ZA (1) ZA200405507B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909793A2 (de) * 2005-07-15 2008-04-16 Proxomed Medizintechnik GmbH Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von erkrankungen oder gesundheitsstörungen, sowie abgabesysteme für dieselben
EP1951237A2 (en) * 2005-11-14 2008-08-06 The Trustees of Columbia University in The City of New York Imaging correlates of neurogenesis with mri
US8841300B2 (en) 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
AU2008254424B2 (en) * 2007-05-18 2012-12-20 Vivus, Inc. Novel combinations comprising a phosphodiesterase-5 inhibitor and their use
US20110104100A1 (en) * 2007-10-04 2011-05-05 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
WO2009059271A1 (en) * 2007-11-02 2009-05-07 University Of Miami Diagnosis and treatment of cardiac disorders
WO2013161913A1 (ja) 2012-04-25 2013-10-31 武田薬品工業株式会社 含窒素複素環化合物
WO2014010732A1 (ja) 2012-07-13 2014-01-16 武田薬品工業株式会社 複素環化合物
JP6338601B2 (ja) * 2013-03-01 2018-06-06 フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ ホスホジエステラーゼとヒストンデアセチラーゼの二重阻害剤としての新規な化合物
WO2014142255A1 (ja) 2013-03-14 2014-09-18 武田薬品工業株式会社 複素環化合物
WO2015002231A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
US10297661B2 (en) * 2017-06-30 2019-05-21 Taiwan Semiconductor Manufacturing Co., Ltd. High voltage resistor device
TWI879058B (zh) * 2023-08-31 2025-04-01 未來新藥股份有限公司 Pde5抑制劑組合於促進神經突生長之新穎用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2187086A1 (en) * 1994-04-15 1995-10-26 Masaomi Iyo A pharmaceutical composition for therapeutically treating tardive dyskinesia and uses therof
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
CA2279651A1 (en) * 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
PT1183035E (pt) * 1999-05-14 2015-03-04 Ford Henry Health System Transplante de medula óssea para tratamento de acidente vascular cerebral
EP1233670B1 (en) * 1999-06-14 2008-09-17 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
IL152925A (en) * 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
US6271228B1 (en) 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
AU2001284792A1 (en) * 2000-08-10 2002-02-25 Cold Spring Harbor Laboratory Augmented cognitive training

Also Published As

Publication number Publication date
JP2005514406A (ja) 2005-05-19
EP1469852A2 (en) 2004-10-27
WO2003056899A3 (en) 2003-11-27
EP1469852A4 (en) 2009-12-02
ZA200405507B (en) 2005-05-25
CA2471147A1 (en) 2003-07-17
CN1638775A (zh) 2005-07-13
AU2003210447A1 (en) 2003-07-24
US20120009152A1 (en) 2012-01-12
JP4545440B2 (ja) 2010-09-15
WO2003056899A9 (en) 2004-04-15
AU2003210447B2 (en) 2008-02-07
US20050143388A1 (en) 2005-06-30
JP2009256374A (ja) 2009-11-05
IL162850A0 (en) 2005-11-20
WO2003056899A2 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
US20120009152A1 (en) Nitric oxide donors for treatment of disease and injury
US9394520B2 (en) Expansion of hematopoietic stem cells
US7658951B2 (en) Method of improving cardiac function of a diseased heart
US8309095B2 (en) Parathyroid hormone receptor activation and stem and progenitor cell expansion
US20030091547A1 (en) Platelet-derived growth factor protection of cardiac myocardium
CZ2004852A3 (cs) Materiály z buněk stromatu kostní dřeně pro použití při tvorbě cév a výrobě angiogenních a trofických faktorů
JP6560332B2 (ja) 単一サイクルでコンディショニングおよび化学選択を組み合わせる方法
US20090092625A1 (en) Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion
CN107548305A (zh) 用于增加移植后造血干细胞的植入疗效的新型组合物
JP2004529916A (ja) パーキンソン病の治療において神経栄養活性化合物と組み合わせたアデノシンａ２ａレセプターアンタゴニスト
JP5500773B2 (ja) 副甲状腺ホルモン受容体の活性化並びに幹細胞及び前駆細胞の増殖
US20170128461A1 (en) Ship inhibition to induce expression of granulocyte colony stimulating factor in a subject
TW202131936A (zh) 動員(mobilization)造血幹細胞及前驅細胞的給藥方案
WO2004105787A1 (en) Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders
US20070244037A1 (en) Human Chemokine HCC-1 Polypeptides To Improve Stem Cell Transplantation
WO2015187847A1 (en) Use of prostaglandin e1 (pge1) and misoprostol for treating chronic myelogenous/myeloid leukemia (cml)
CA3168806A1 (en) Therapeutic exosomes and method of producing them
AU2002339944A1 (en) Cardiac transplantation of stem cells for the treatment of heart failure

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170106